Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Reviva Pharmaceuticals HoldingsRVPH -4.40%21 3-Year Share Buyback Ratio is -79.10 as of Jun. 2026. GuruFocus rates RVPH with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,184 Biotechnology companies, Reviva Pharmaceuticals Holdings ranks worse than 88.85% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Reviva Pharmaceuticals Holdings's current 3-Year Share Buyback Ratio was -79.10%.
The historical rank and industry rank for Reviva Pharmaceuticals Holdings's 3-Year Share Buyback Ratio or its related term are showing as below:
RVPH'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -94.5 Med: -63.45 Max: -44.6
Current: -79.1
During the past 7 years, Reviva Pharmaceuticals Holdings's highest 3-Year Share Buyback Ratio was -44.60%. The lowest was -94.50%. And the median was -63.45%.
RVPH's 3-Year Share Buyback Ratio is ranked worse than 88.85% of 1184
companies
in the Biotechnology industry
Industry Median: -11.6
vs RVPH: -79.10
Reviva Pharmaceuticals Holdings (OTCPK:RVPH) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Reviva Pharmaceuticals Holdings 3-Year Share Buyback Ratio Related Terms
RVPH vs ADTX, DRMA, CLGN: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reviva Pharmaceuticals Holdings 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Reviva Pharmaceuticals Holdings's 3-Year Share Buyback Ratio falls into.
Reviva Pharmaceuticals Holdings 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -79.10 mean?
Reviva Pharmaceuticals Holdings (RVPH) has a 3-Year Share Buyback Ratio of -79.10 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Reviva Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #1052 out of 1184 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Reviva Pharmaceuticals Holdings' 3-Year Share Buyback Ratio too high?
Reviva Pharmaceuticals Holdings' current 3-Year Share Buyback Ratio is -79.10. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #1052 out of 1184 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' 3-Year Share Buyback Ratio compare to ADTX and DRMA?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #1052 out of 1184 companies for 3-Year Share Buyback Ratio. This places Reviva Pharmaceuticals Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current 3-Year Share Buyback Ratio is -79.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current 3-Year Share Buyback Ratio of -79.10. The current 3-Year Share Buyback Ratio is -79.10. Reviva Pharmaceuticals Holdings' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current 3-Year Share Buyback Ratio is -79.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
21GF Score
Get the complete analysis for RVPH
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVPH has been successfully added to your 
